Ankur Sharma

Dr. Ankur Sharma

Assistant Professor, Department of Life Science, School of Basic Science & Research, Sharda University, Greater Noida, Room # 311, Block-01, Plot No. 32-34, Knowledge Park III, Greater Noida, Uttar Pradesh 201310, India

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2023 in Molecules
Verified
Journal Article
Open access
PDF file
SSSAYED SARTAJ SOHRAB
SAYED SARTAJ SOHRAB
RRRiya Raj
Riya Raj
ANAmka Nagar
Amka Nagar
Susan HawthorneSusan Hawthorne
Susan Hawthorne
Ana Cláudia Paiva-SantosAna Cláudia Paiva-Santos
Ana Cláudia Paiva-Santos
Ankur SharmaAnkur Sharma
Ankur Sharma
The body’s normal immune response against any invading pathogen that causes infection in the body results in inflammation. The sudden transformation in inflammation leads to the rise of inflammatory diseases such as chronic inflammatory bowel disease, autoimmune disorders, and colorectal cancer (different types of cancer develop at the site of chronic infection and inflammation). Inflammation results in two ways: short-term inflammation i.e., non-specific, involves the action of various immune cells; the other results in long-term reactions lasting for months or years. It is specific and causes angiogenesis, fibrosis, tissue destruction, and cancer progression at the site of inflammation. Cancer progression relies on the interaction between the host microenvironment and tumor cells along with the inflammatory responses, fibroblast, and vascular cells. The two pathways that have been identified connecting inflammation and cancer are the extrinsic and intrinsic pathways. Both have their own specific role in linking inflammation to cancer, involving various transcription factors such as Nuclear factor kappa B, Activator of transcription, Single transducer, and Hypoxia-inducible factor, which in turn regulates the inflammatory responses via Soluble mediators cytokines (such as Interleukin-6, Hematopoietin-1/Erythropoietin, and tumor necrosis factor), chemokines (such as Cyclooxygenase-2, C-X-C Motif chemokines ligand-8, and IL-8), inflammatory cells, cellular components (such as suppressor cells derived from myeloid, tumor-associated macrophage, and acidophils), and promotes tumorigenesis. The treatment of these chronic inflammatory diseases is challenging and needs early detection and diagnosis. Nanotechnology is a booming field nowadays for its rapid action and easy penetration inside the infected destined cells. Nanoparticles are widely classified into different categories based on their different factors and properties such as size, shape, cytotoxicity, and others. Nanoparticles emerged as excellent with highly progressive medical inventions to cure diseases such as cancer, inflammatory diseases, and others. Nanoparticles have shown higher binding capacity with the biomolecules in inflammation reduction and lowers the oxidative stress inside tissue/cells. In this review, we have overall discussed inflammatory pathways that link inflammation to cancer, major inflammatory diseases, and the potent action of nanoparticles in chronic inflammation-related diseases.

22 November 2019 in Genes
Verified
Journal Article
Open access
PDF file
RKRohan Kar
Rohan Kar
Niraj Kumar JhaNiraj Kumar Jha
Niraj Kumar Jha
Saurabh Kumar JhaSaurabh Kumar Jha
Saurabh Kumar Jha
Ankur SharmaAnkur Sharma
Ankur Sharma
SDSunny Dholpuria
Sunny Dholpuria
Parma NandParma Nand
Parma Nand
Notch signaling is a primitive signaling pathway having various roles in the normal origin and development of each multicellular organisms. Therefore, any aberration in the pathway will inevitably lead to deadly outcomes such as cancer. It has now been more than two decades since Notch was acknowledged as an oncogene in mouse mammary tumor virus-infected mice. Since that discovery, activated Notch signaling and consequent up-regulation of tumor-promoting Notch target genes have been observed in human breast cancer. Moreover, consistent over-expression of Notch ligands and receptors has been shown to correlate with poor prognosis in human breast cancer. Notch regulates a number of key processes during breast carcinogenesis, of which, one key phenomenon is epithelial–mesenchymal transition (EMT). EMT is a key process for large-scale cell movement during morphogenesis at the time of embryonic development. Cancer cells aided by transcription factors usurp this developmental program to execute the multi-step process of tumorigenesis and metastasis. In this review, we recapitulate recent progress in breast cancer research that has provided new perceptions into the molecular mechanisms behind Notch-mediated EMT regulation during breast tumorigenesis.

20 October 2021 in Brain Sciences
Verified
Journal Article
Open access
PDF file
SAShashank Vishwanath Adhikarla
Shashank Vishwanath Adhikarla
Niraj Kumar JhaNiraj Kumar Jha
Niraj Kumar Jha
VGVineet Kumar Goswami
Vineet Kumar Goswami
Ankur SharmaAnkur Sharma
Ankur Sharma
ABAnuradha Bhardwaj
Anuradha Bhardwaj
Saurabh Kumar JhaSaurabh Kumar Jha
Saurabh Kumar Jha
A special class of proteins called Toll-like receptors (TLRs) are an essential part of the innate immune system, connecting it to the adaptive immune system. There are 10 different Toll-Like Receptors that have been identified in human beings. TLRs are part of the central nervous system (CNS), showing that the CNS is capable of the immune response, breaking the long-held belief of the brain’s “immune privilege” owing to the blood–brain barrier (BBB). These Toll-Like Receptors are present not just on the resident macrophages of the central nervous system but are also expressed by the neurons to allow them for the production of proinflammatory agents such as interferons, cytokines, and chemokines; the activation and recruitment of glial cells; and their participation in neuronal cell death by apoptosis. This study is focused on the potential roles of various TLRs in various neurodegenerative diseases such as Parkinson’s disease (PD) and Alzheimer’s disease (AD), namely TLR2, TLR3, TLR4, TLR7, and TLR9 in AD and PD in human beings and a mouse model.

23 November 2023 in Applied Materials Today
Verified
Journal Article
Open access
JDJoana Galvão Duarte
Joana Galvão Duarte
Ankur SharmaAnkur Sharma
Ankur Sharma
ESEsmaeel Sharifi
Esmaeel Sharifi
FOUAD DAMIRIFOUAD DAMIRI
FOUAD DAMIRI
MBMohammed Berrada
Mohammed Berrada
Ana Cláudia Paiva-SantosAna Cláudia Paiva-Santos
Ana Cláudia Paiva-Santos

23 July 2021 in Nanomedicine
Verified
Journal Article
Open access
Ankur SharmaAnkur Sharma
Ankur Sharma
SHSusan Hawthorne
Susan Hawthorne
SJSaurabh Kumar Jha
Saurabh Kumar Jha
Niraj Kumar JhaNiraj Kumar Jha
Niraj Kumar Jha
DKDhruv Kumar
Dhruv Kumar
Kamal DuaKamal Dua
Kamal Dua
Aim: This study was aimed at evaluating the anticancer potential of curcumin-loaded poly(lactic-co-glycolic acid) (PLGA) based nanoparticles (NPs) in MDA-MB231 human breast cancer cells. Methods: C...

6 April 2021 in Cancer Reports
Verified
Journal Article
Open access
PDF file
RKRohan Kar
Rohan Kar
Saurabh Kumar JhaSaurabh Kumar Jha
Saurabh Kumar Jha
Shreesh  OjhaShreesh Ojha
Shreesh Ojha
Ankur SharmaAnkur Sharma
Ankur Sharma
SDSunny Dholpuria
Sunny Dholpuria
Niraj Kumar JhaNiraj Kumar Jha
Niraj Kumar Jha
Background: Ubiquitin ligases or E3 ligases are well programmed to regulate molecular interactions that operate at a post‐translational level. Skp, Cullin, F‐box containing complex (or SCF complex) is a multidomain E3 ligase known to mediate the degradation of a wide range of proteins through the proteasomal pathway. The three‐dimensional domain architecture of SCF family proteins suggests that it operates through a novel and adaptable “super‐enzymatic” process that might respond to targeted therapeutic modalities in cancer.Recent findings: Several F‐box containing proteins have been characterized either as tumor suppressors (FBXW8, FBXL3, FBXW8, FBXL3, FBXO1, FBXO4, and FBXO18) or as oncogenes (FBXO5, FBXO9, and SKP2). Besides, F‐box members like βTrcP1 and βTrcP2, the ones with context‐dependent functionality, have also been studied and reported. FBXW7 is a well‐studied F‐box protein and is a tumor suppressor. FBXW7 regulates the activity of a range of substrates, such as c‐Myc, cyclin E, mTOR, c‐Jun, NOTCH, myeloid cell leukemia sequence‐1 (MCL1), AURKA, NOTCH through the well‐known ubiquitin‐proteasome system (UPS)‐mediated degradation pathway. NOTCH signaling is a primitive pathway that plays a crucial role in maintaining normal tissue homeostasis. FBXW7 regulates NOTCH protein activity by controlling its half‐life, thereby maintaining optimum protein levels in tissue. However, aberrations in the FBXW7 or NOTCH expression levels can lead to poor prognosis and detrimental outcomes in patients. Therefore, the FBXW7‐NOTCH axis has been a subject of intense study and research over the years, especially around the interactome's role in driving cancer development and progression. Several studies have reported the effect of FBXW7 and NOTCH mutations on normal tissue behavior. The current review attempts to critically analyze these mutations prognostic value in a wide range of tumors. Furthermore, the review summarizes the recent findings pertaining to the FBXW7 and NOTCH interactome and its involvement in phosphorylation‐related events, cell cycle, proliferation, apoptosis, and metastasis.Conclusion: The review concludes by positioning FBXW7 as an effective diagnostic marker in tumors and by listing out recent advancements made in cancer therapeutics in identifying protocols targeting the FBXW7‐NOTCH aberrations in tumors.